A Phase I Study of Temsirolimus and Bryostatin-1 in Patients With Metastatic Renal Cell Carcinoma and Soft Tissue Sarcoma

BACKGROUND. Temsirolimus, an inhibitor of mammalian target of rapamycin (mTOR) complex 1, is approved for the treatment of metastatic renal cell carcinoma (RCC). Bryostatin-1 inhibits protein kinase C, a downstream effector of mTOR complex 2. We observed antitumor effects with the combination of tem...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Plimack, Elizabeth R., Tan, Tingting, Wong, Yu-Ning, von Mehren, Margaret M., Malizzia, Lois, Roethke, Susan K., Litwin, Samuel, Li, Tianyu, Hudes, Gary R., Haas, Naomi B.
Formato: Artigo
Idioma:Inglês
Publicado em: AlphaMed Press 2014
Assuntos:
Clinical Trial Results
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3983829/
https://ncbi.nlm.nih.gov/pubmed/24674872
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2014-0020
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados